GlobeNewswire: Sio Gene Therapies, Inc. Contains the last 10 of 96 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T09:12:17ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/02/2822755/0/en/Sio-Gene-Therapies-Inc-to-File-for-Dissolution-and-Declare-an-Initial-Liquidating-Distribution-of-0-435-Per-Share.html?f=22&fvtc=4&fvtv=40626Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share2024-02-02T12:00:00Z<![CDATA[PARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. ("Sio") today announced that it expects to file a certificate of dissolution (the "Certificate of Dissolution") with the Secretary of State of the State of Delaware, as contemplated by the Plan of Complete Liquidation and Dissolution (the "Plan") previously approved by Sio's Board of Directors and stockholders, on February 7, 2024. The Certificate of Dissolution, which is expected to become effective at 4:00 p.m. Eastern Time on February 7, 2024 (the "Effective Time"), provides for the dissolution of Sio under the General Corporation Law of the State of Delaware (the "DGCL").]]>https://www.globenewswire.com/news-release/2023/02/14/2607458/0/en/Sio-Gene-Therapies-Announces-Fiscal-Third-Quarter-2022-Financial-Results.html?f=22&fvtc=4&fvtv=40626Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results2023-02-14T12:00:00Z<![CDATA[– Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively]]>https://www.globenewswire.com/news-release/2022/12/14/2574108/0/en/Sio-Gene-Therapies-Inc-Announces-Board-Approval-of-Plan-of-Complete-Liquidation-and-Dissolution.html?f=22&fvtc=4&fvtv=40626Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution2022-12-14T21:49:48Z<![CDATA[NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (Nasdaq:SIOX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets, including its subsidiaries.]]>https://www.globenewswire.com/news-release/2022/11/10/2552981/0/en/Sio-Gene-Therapies-Announces-Fiscal-Second-Quarter-2022-Financial-Results.html?f=22&fvtc=4&fvtv=40626Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results2022-11-10T12:00:00Z<![CDATA[- Three-Month and Six-Month Losses decline by 85.5% and 65.3%, respectively]]>https://www.globenewswire.com/news-release/2022/08/11/2496586/0/en/Sio-Gene-Therapies-Announces-Fiscal-First-Quarter-2022-Financial-Results.html?f=22&fvtc=4&fvtv=40626Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results 2022-08-11T11:00:00Z<![CDATA[— Strong cash position with $54.8 million of cash and cash equivalents as of June 30, 2022, expected to provide cash runway beyond August 2023]]>https://www.globenewswire.com/news-release/2021/03/15/2192648/0/en/Sio-Gene-Therapies-Provides-Update-on-Cash-Position-and-Major-Upcoming-GM1-Gangliosidosis-Program-Milestones.html?f=22&fvtc=4&fvtv=40626Sio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program Milestones2021-03-15T11:00:00Z<![CDATA[NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 15, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it had $120.9 million in cash and cash equivalents as of March 12, 2021, augmented by a recent $15 million equity investment by Suvretta Capital.]]>https://www.globenewswire.com/news-release/2021/03/11/2191323/0/en/Sio-Gene-Therapies-to-Participate-in-Upcoming-Investor-Scientific-Conferences.html?f=22&fvtc=4&fvtv=40626Sio Gene Therapies to Participate in Upcoming Investor & Scientific Conferences2021-03-11T13:00:00Z<![CDATA[NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor and scientific conferences. Details can be found below.]]>https://www.globenewswire.com/news-release/2021/02/16/2175920/0/en/Sio-Gene-Therapies-to-Present-at-the-10th-Annual-SVB-Leerink-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=40626Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference2021-02-16T12:00:00Z<![CDATA[NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will present at the 10th Annual SVB Leerink Global Healthcare Conference taking place February 22-26, 2021. Details on the presentation can be found below.]]>https://www.globenewswire.com/news-release/2021/02/09/2172067/0/en/Sio-Gene-Therapies-Announces-Financial-Results-for-Third-Fiscal-Quarter-Ended-December-31-2020.html?f=22&fvtc=4&fvtv=40626Sio Gene Therapies Announces Financial Results for Third Fiscal Quarter Ended December 31, 20202021-02-09T12:00:00Z<![CDATA[- Company had $81 million of cash and cash equivalents as of December 31, 2020, and expects to receive additional $16 million in cash in 2021 from sale of Arvelle Therapeutics shares - Cash runway expected into the second calendar quarter of 2022]]>https://www.globenewswire.com/news-release/2021/02/04/2169784/0/en/Sio-Gene-Therapies-Announces-Receipt-of-11-6-Million-from-Closing-of-the-Sale-of-Arvelle-Therapeutics.html?f=22&fvtc=4&fvtv=40626Sio Gene Therapies Announces Receipt of $11.6 Million from Closing of the Sale of Arvelle Therapeutics2021-02-04T12:00:00Z<![CDATA[Company expects to receive an additional $4.8 million by mid-2021 upon approval of cenobamate in Europe, totaling over $16.4 million in aggregate net proceeds this year Company expects to receive an additional $4.8 million by mid-2021 upon approval of cenobamate in Europe, totaling over $16.4 million in aggregate net proceeds this year]]>